The DOI matches its Crossref record, with a small difference in title or year; 15 of the 15 references it cites were found in a registry or an index.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk of DKA is increased in persons using SGLT2is, especially in those being treated with insulin (especially if there has been a recent reduction in their insulin dose) and/or those with acute illnesses and prolonged fasting.1049,1050”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1049]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) and DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), SGLT2 inhibition reduced the risk of cardiovascular death and worsening HF events by 18% to 21%4,5 and improved KCCQ-CSS by 1.5 to 2.3 points”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [290]
In the citing paper
“Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalization by 22% in those with an LVEF below or equal to the median of 57%.534”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“DELIVER recruited 6263 patients with heart failure with mildly reduced or preserved (>40%) ejection fraction including 3109 patients without diabetes.”
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
In the citing paper
“Approximately 44% of patients randomized to either dapaglifl ozin or placebo had type 2 diabetes, and results were consistent regardless of the presence of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
In the citing paper
“The primary outcome of a composite of worsening heart failure, de fi ned as hospitalization or urgent visit for heart failure, or cardiovascular death was reduced by 18% in patients treated with dapagli fl ozin compared with placebo (HR 0.82 [95% CI 0.73 -0.92]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCategorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 2,034
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationSolomon, S. D., Claggett, B. L., Lewis, E. F., Desai, A. S., Anand, I. S., Sweitzer, N. K., O’Meara, E., Shah, S. J., McKinlay, S. M., Fleg, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 538
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,002
Mori, Y., Duru, O. K., Tuttle, K. R., Fukuma, S., Taura, D., Harada, N., Inagaki, N., & Inoue, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac591 · Cited by 48
The Win Ratio Method in Heart Failure Trials: Lessons Learnt from EMPULSE
Pocock, S., Ferreira, J. P., Collier, T. J., Angermann, C. E., Biegus, J., Collins, S. P., Kosiborod, M., Nassif, M. E., Ponikowski, P. P., Psotka, M. A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2853 · Cited by 47
Self-citationHeart Failure in Patients with Chronic Kidney Disease
Xanthopoulos, A. V., Papamichail, A., Briasoulis, Α., Loritis, K., Bourazana, A., Magouliotis, D. E., Sarafidis, P. A., Stefanidis, I., Skoularigis, J. S., & Triposkiadis, F. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186105 · Cited by 56
Wang, W., Li, Y., Zhang, Y., Ye, T., Wang, K., Li, S., & Zhang, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02040-x · Cited by 49
Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians
Wu, L., Rodríguez, M., Hachem, K. E., & Krittanawong, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154470 · Cited by 71
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
Podestà, M. A., Sabiu, G., Galassi, A., Ciceri, P., & Cozzolino, M. G. (2023) · Biomedicines · doi:10.3390/biomedicines11020279 · Cited by 47
Rivera, F. B., Tang, V. A. S., Luna, D. V. D., Lerma, E. V., Vijayaraghavan, K., Kazory, A., Shah, N. S., & Volgman, A. S. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100261 · Cited by 48
Stoicescu, L., Crișan, D., Morgovan, C., Avram, L., & Ghibu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020794 · Cited by 57
SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Mariani, M. V., Manzi, G., Pierucci, N., Laviola, D., Piro, A., D’Amato, A., Filomena, D., Matteucci, A., Severino, P., Miraldi, F., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16344 · Cited by 48
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
Luo, L., Zuo, Y., & Dai, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02707-7 · Cited by 54
The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction
Janssen-Telders, C., Eringa, E. C., de Groot, J. R., de Man, F. S., & Handoko, M. L. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf056 · Cited by 57
Ostrominski, J. W., Thierer, J. M., Claggett, B. L., Miao, Z. M., Desai, A. S., Jhund, P. S., Kosiborod, M., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.015 · Cited by 48
Self-citationInzucchi, S. E., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Kosiborod, M., Lam, C. S. P., Martínez, F. A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00308-4 · Cited by 51
Self-citationRodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 46
Sachdev, V., Sharma, K., Keteyian, S. J., Alcain, C. F., Desvigne-Nickens, P. M., Fleg, J. L., Florea, V. G., Franklin, B. A., Guglin, M. E., Halle, M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.012 · Cited by 45
Kani, R., Watanabe, A., Miyamoto, Y., Ejiri, K., Iwagami, M., Takagi, H., Slipczuk, L. N., Tsugawa, Y., Aikawa, T., & Kuno, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031805 · Cited by 46
The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 52
The Evolving Concept of Secondary Mitral Regurgitation Phenotypes
Stolz, L., Doldi, P. M., Sannino, A., Hausleiter, J., & Grayburn, P. A. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.01.012 · Cited by 45
Myocardial ultrastructure of human heart failure with preserved ejection fraction
Meddeb, M., Koleini, N., Binek, A., Keykhaei, M., Darehgazani, R., Kwon, S., Aboaf, C. C., Margulies, K. B., Bedi, K., Lehar, M., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00516-x · Cited by 41
Benedikt, M., Mangge, H., Aziz, F., Curcic, P., Pailer, S., Herrmann, M., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Wallner, M., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01904-6 · Cited by 44
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Chen, J., Pan, H., Shiao, C., Chuang, M., See, C. Y., Yeh, T.-H., Yang, Y., Chu, W.-K., & Wu, V. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02035-8 · Cited by 44
Causland, F. R. M., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Vardeny, O., Fang, J. C.-T., de Boer, R. A., Docherty, K. F., Hernandez, A. F., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4664 · Cited by 43
Self-citationObesity: The Perfect Storm for Heart Failure
Lembo, M., Strisciuglio, T., Fonderico, C., Mancusi, C., Izzo, R., Trimarco, V., Bellis, A., Barbato, E., Esposito, G., Morisco, C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14641 · Cited by 51
Bansal, N., Zelnick, L. R., Scherzer, R., Estrella, M. M., & Shlipak, M. G. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.011173 · Cited by 44
Ottosen, C. I., Nadruz, W., Inciardi, R. M., Johansen, N. D., Fudim, M., & Biering‐Sørensen, T. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae178 · Cited by 45
van Ommen, A. M. L. N., Canto, E. D., Cramer, M. J., Rutten, F. H., Onland‐Moret, N. C., & den Ruijter, H. M. (2022) · BMC Medicine · doi:10.1186/s12916-022-02650-4 · Cited by 40
Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
Chen, K., Nie, Z., Shi, R., Yu, D., Wang, Q., Shao, F., Wu, G., Wu, Z., Chen, T., & Li, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.30754 · Cited by 41
Young, K., McInnes, E. H., Massey, R. J., Kahkoska, A. R., Pilla, S. J., Raghavan, S., Stanislawski, M. A., Tobias, D. K., McGovern, A. P., Dawed, A. Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00359-w · Cited by 44
Chen, J., Jiang, C., Guo, M., Zeng, Y., Jiang, Z., Zhang, D., Tu, M., Tan, X., Yan, P., Xu, X.-M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02042-9 · Cited by 49
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
von Haehling, S., Aßmus, B., Bekfani, T., Dworatzek, E., Edelmann, F., Hashemi, D., Hellenkamp, K., Kempf, T., Raake, P., Schütt, K. A., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02396-4 · Cited by 49
Abdin, A., Böhm, M., Shahim, B., Karlström, P., Kulenthiran, S., Skouri, H. N., & Lund, L. H. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132304 · Cited by 48
Shi, Y., Zhao, L., Wang, J., Liu, X., Bai, Y., Cong, H., & Li, X. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02366-0 · Cited by 40
Tada, A., Burkhoff, D., Naser, J. A., Harada, T., Pourmussa, B., Reddy, Y. N. V., Jensen, M. D., Carter, R. E., Demmer, R. T., Testani, J. M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.068788 · Cited by 42
Akerman, A. P., Al-Roub, N., Angell-James, C. E. M., Cassidy, M. A., Thompson, R. A. M., Bosque, L., Rainer, K., Hawkes, W., Piotrowska, H., Leeson, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58283-7 · Cited by 41
Gregson, J., Taylor, D., Owen, R., Collier, T. J., Cohen, D. J., & Pocock, S. (2025) · Circulation · doi:10.1161/circulationaha.124.070251 · Cited by 45
Cardiovascular aging: from cellular and molecular changes to therapeutic interventions
Vakka, A., Warren, J. S., & Drosatos, K. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.09 · Cited by 44
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
Peh, Z. H., Dihoum, A., Hutton, D. L., Arthur, J. S. C., Rena, G., Khan, F., Lang, C. C., & Mordi, I. R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1125687 · Cited by 46
Saito, Y., Obokata, M., Harada, T., Kagami, K., Wada, N., Okumura, Y., & Ishii, H. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad127 · Cited by 40
Chatur, S., Vaduganathan, M., Claggett, B. L., Cunningham, J. W., Docherty, K. F., Desai, A. S., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.066506 · Cited by 39
Self-citationFazio, S., Mercurio, V., Tibullo, L., Fazio, V., & Affuso, F. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1380506 · Cited by 46
D’Amario, D., Laborante, R., Bianchini, E., Ciliberti, G., Paglianiti, D. A., Galli, M., Restivo, A., Stolfo, D., Vergallo, R., Rosano, G. M. C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14626 · Cited by 42
Self-citationJames, S. K., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Björkgren, I., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Rizi, E. P., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.08.008 · Cited by 38
Self-citationSodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use
Siafarikas, C., Kapelios, C. J., Papatheodoridi, Μ., Vlachogiannakos, J., Tentolouris, N., & Papatheodoridis, G. (2024) · Liver International · doi:10.1111/liv.15851 · Cited by 40
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Yokose, C., McCormick, N., Abhishek, A., Dalbeth, N., Pascart, T., Lioté, F., Gaffo, A., FitzGerald, J. D., Terkeltaub, R. A., Sise, M. E., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01092-x · Cited by 42
Lenselink, C., Ricken, K. W. L. M., Groot, H. E., de Bruijne, T., Hendriks, T., van der Harst, P., Voors, A. A., & Lipšic, E. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3225 · Cited by 37
Garred, C. H., Malmborg, M. W., Malik, M. E., Zahir, D., Christensen, D. M., Arulmurugananthavadivel, A., Fosbøl, E. L., Gislason, G., McMurray, J. J. V., Petrie, M. C., et al. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00029-1 · Cited by 38
Self-citationDiabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction
Hegyi, B., Hernández, J. M., Ko, C. Y., Hong, J., Shen, E. Y., Spencer, E. R., Smoliarchuk, D., Navedo, M. F., Bers, D. M., & Bossuyt, J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.027164 · Cited by 39
Sotomi, Y., Hikoso, S., Nakatani, D., Okada, K., Dohi, T., Sunaga, A., Kida, H., Sato, T., Matsuoka, Y., Kitamura, T., et al. (2023) · Heart · doi:10.1136/heartjnl-2022-322181 · Cited by 38
Rastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
Monzo, L., Ferrari, I., Cicogna, F., Tota, C., Cice, G., Girerd, N., & Calò, L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad055 · Cited by 38
Cistulli, P. A., Malhotra, A., Cole, K. V., Malik, A., Pépin, J., Kuniyoshi, F. H. S., Benjafield, A., Somers, V. K., Cistulli, P. A., Malhotra, A., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028733 · Cited by 37
Meijs, C. M. E. M., Handoko, M. L., Savarese, G., Vernooij, R. W. M., Vaartjes, I. C. H., Banerjee, A., Koudstaal, S., Brugts, J. J., Asselbergs, F. W., & Uijl, A. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00615-z · Cited by 40
Updates on New Therapies for Patients with CKD
Tarun, T., Ghanta, S. N., Ong, V., Kore, R. A., Menon, L., Kovesdy, C. P., Mehta, J. L., & Jain, N. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.006 · Cited by 43
Cheng, X., Zhao, H., Wen, X., Li, G., Guo, S., & Zhang, D. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122185 · Cited by 37
Sex-related similarities and differences in responses to heart failure therapies
Chyou, J. Y., Qin, H., Butler, J., Voors, A. A., & Lam, C. S. P. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00996-1 · Cited by 37
Self-citationConnelly, K. A., Mazer, C. D., Puar, P., Teoh, H., Wang, C., Mason, T., Akhavein, F., Chang, C., Liu, M., Yang, N., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.062769 · Cited by 38
Self-citationAdejumo, P., Thangaraj, P. M., Dhingra, L. S., Aminorroaya, A., Zhou, X., Brandt, C., Xu, H., Krumholz, H. M., & Khera, R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.43925 · Cited by 36
Banerjee, M., Pal, R., Nair, K., & Mukhopadhyay, S. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.03.003 · Cited by 41
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy
Witteles, R. M., García‐Pavía, P., Damy, T., Grogan, M. A., Sheikh, F. H., Morbach, C., Bender, S. D., Exter, J., Eraly, S. A., & Fontana, M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.008 · Cited by 37
Butt, J. H., Kondo, T., Yang, M., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Claggett, B. L., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad276 · Cited by 36
Self-citationKarakasis, P., Pamporis, K., Stachteas, P., Patoulias, D., Bougioukas, K. I., & Fragakis, N. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10324-3 · Cited by 35
Müllens, W., Dauw, J., Gustafsson, F., Mebazaa, A., Steffel, J., Witte, K. K., Delgado, V., Linde, C. M., Vernooy, K., Anker, S. D., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3150 · Cited by 35
Koleini, N., Meddeb, M., Zhao, L., Keykhaei, M., Kwon, S., Farshidfar, F., Hahn, V. S., Pearce, E. L., Sharma, K., & Kass, D. A. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3389 · Cited by 35
Aggarwal, R., Bhatt, D. L., Szarek, M. J., Cannon, C. P., Leiter, L. A., Inzucchi, S. E., Lópes, R. D., McGuire, D. K., Lewis, J. B., Riddle, M. C., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00362-0 · Cited by 38
Self-citationHulot, J., ter Maaten, J. M., Bayés‐Genís, A., Halliday, B. P., Metra, M., Moura, B., Petrie, M. C., Savarese, G., Senni, M., Linhout, S. V., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3732 · Cited by 39
Heart failure with reduced ejection fraction
Cannata, A. N., Crespo-Leiro, M. G., Bromage, D. I., Ruschitzka, F., & McDonagh, T. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01851-3 · Cited by 38
Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., de Boer, R. A., Desai, A. S., Dobreanu, D., Hernandez, A. F., Inzucchi, S. E., Jhund, P. S., Kosiborod, M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2652 · Cited by 36
Self-citationYang, M., Butt, J. H., Kondo, T., Jering, K., Docherty, K. F., Jhund, P. S., de Boer, R. A., Claggett, B. L., Desai, A. S., Hernandez, A. F., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2722 · Cited by 35
Self-citationCostanzo, A. D., Esposito, G., Indolfi, C., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108732 · Cited by 40
Liew, A., Lydia, A., Matawaran, B. J., Susantitaphong, P., Tran, H. T. B., & Lim, L. (2023) · Nephrology · doi:10.1111/nep.14167 · Cited by 36
Lim, J., Choi, Y.-J., Kim, B. S., Rhee, T., Lee, H.-J., Han, K. D., Park, J., Na, J. O., Kim, Y.-J., Lee, H., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01911-7 · Cited by 33
Mentz, R. J., Brunton, S., & Rangaswami, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02023-y · Cited by 38
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 34
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Abdelgani, S., Khattab, A., Adams, J. M., Baskoy, G., Brown, M., Clarke, G., Larvenenko, O., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-1646 · Cited by 37
de Miguel‐Díez, J., Villota, J. N., Santos, S., Lorite, N. M., Navarrete, B. A., Delgado, J. F., Soler‐Cataluña, J. J., Pascual-Figal, D. A., Ecenarro, P. S., & Gómez‐Doblas, J. J. (2024) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2024.01.013 · Cited by 37
SGLT2 Inhibitors in Kidney Diseases—A Narrative Review
Gajewska, A., Wasiak, J., Sapeda, N., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094959 · Cited by 39
Lund, L. H., James, S. K., DeVore, A. D., Anstrom, K. J., Fudim, M., Aaronson, K. D., Dahlström, U., Desvigne-Nickens, P. M., Fleg, J. L., Yang, S., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3453 · Cited by 36
Basile, C., Lindberg, F., Benson, L., Guidetti, F., Dahlström, U., Piepoli, M. F., Mol, P. G. M., Scorza, R., Maggioni, A. P., Lund, L. H., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072855 · Cited by 40
The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
Cinti, F., Laborante, R., Cappannoli, L., Morciano, C., Gugliandolo, S., Pontecorvi, A., Burzotta, F., Donniacuo, M., Cappetta, D., Patti, G., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02767-9 · Cited by 38
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
Solomon, J., Festa, M. C., Chatzizisis, Y. S., Samanta, R., Suri, R. S., & Mavrakanas, T. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108330 · Cited by 34
Castiglione, V., Gentile, F., Ghionzoli, N., Chiriacò, M., Panichella, G., Aimo, A., Vergaro, G., Giannoni, A., Passino, C., & Emdin, M. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.23 · Cited by 35
Gonzalez, J., & Dave, C. V. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03961-5 · Cited by 35
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 36
Docherty, K. F., Bayés‐Genís, A., Butler, J., Coats, A. J. S., Drazner, M. H., Joyce, E., & Lam, C. S. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac113 · Cited by 40
Self-citationSex Differences in Heart Failure: What Do We Know?
Arata, A., Ricci, F., Khanji, M. Y., Mantini, C., Angeli, F., Aquilani, R., Baldassarre, A. D., Renda, G., Mattioli, A. V., Nodari, S., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070277 · Cited by 33
Escobar, C., Palacios, B., Varela, L. F., Gutiérrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hernández, I., Hunt, P. R., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08614-x · Cited by 34
Advances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 38
Çınar, T., Şaylık, F., Çiçek, V., Pay, L., Khachatryan, A., Alejandro, J., Erdem, A., & Hayıroğlu, M. İ. (2024) · Kardiologia Polska · doi:10.33963/v.phj.100199 · Cited by 32
Girardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Selvaraj, S., Vaduganathan, M., Claggett, B. L., Miao, Z. M., Fang, J. C., Vardeny, O., Desai, A. S., Shah, S. J., Lam, C. S. P., Martínez, F. A., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.09.002 · Cited by 33
Self-citationOsto, E., Bonacina, F., Pirillo, A., & Norata, G. D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106667 · Cited by 35
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
Tamargo, J. L., Agewall, S., Borghi, C., Ceconi, C., Cerbai, E., Dan, G. A., Ferdinandy, P., Grove, E. L., Rocca, B., Sulzgruber, P., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad034 · Cited by 33
Lyu, Y. S., Oh, S. K., Kim, J. H., Kim, S. Y., & Jeong, M. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01914-4 · Cited by 32
Nakamaru, R., Kohsaka, S., Shiraishi, Y., Kohno, T., Goda, A., Nagatomo, Y., Kitamura, M., Nakano, S., Takei, M., Mizuno, A., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031179 · Cited by 31
Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
Dimond, M. G., Ibrahim, N. E., Fiuzat, M., McMurray, J. J. V., Lindenfeld, J. M., Ahmad, T., Bozkurt, B., Bristow, M. R., Butler, J., Carson, P. E., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.11.005 · Cited by 37
Self-citationChronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 34
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 33
Jaiswal, A., Jaiswal, V., Ang, S. P., Hanif, M., Vadhera, A., Agrawal, V., Kumar, T., Nair, A. M., Borra, V., Garimella, V., et al. (2023) · Medicine · doi:10.1097/md.0000000000034693 · Cited by 41
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer-Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O’Meara, E., Saraiva, J. F. K., Tereshchenko, S. N., Thierer, J., Vaduganathan, M., Vardeny, O., Verma, S., Pham, V. N., Wilderäng, U., Zaozerska, N., Bachus, E., Lindholm, D., Petersson, M., & Langkilde, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norbert...
- Northwestern University (US)
- Semmelweis University (HU)
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Claggett, Brian
- de Boer, Rudolf A.
- DeMets, David
- Hernandez, Adrian F.
- Inzucchi, Silvio E.
- Kosiborod, Mikhail N.
- Lam, Carolyn S.P.
- Shah, Sanjiv J.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Chiang, Chern-En
- Dobreanu, Dan
- Fang, James C.
- Alcocer-Gamba, Marco Antonio
- Han, Yaling
- Janssens, Stefan P.
- Kitakaze, Masafumi
- Merkely, Béla
- O’Meara, Eileen
- Tereshchenko, Sergey N.
- Thierer, Jorge
- Vaduganathan, Muthiah
- Vardeny, Orly
- Verma, Subodh
- Pham, Vinh Nguyen
- Wilderäng, Ulrica
- Bachus, Erasmus
- Lindholm, Daniel
- Petersson, Magnus
- Langkilde, Anna Maria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1089-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293354639
- Cited by
- 2,884
- References
- 15
- Citations by year
- 2026: 635 · 2025: 716 · 2024: 714 · 2023: 673 · 2022: 139
- FWCI
- 390.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure, preserved ejection fraction, mildly reduced ejection fraction, heart failure hospitalization, cardiovascular mortality, left ventricular ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
